Case Studies

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...

Challenge: Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related...

Alacrita's consulting team supports a number of pharmaceutical & biotech companies with medical and clinical strategy. We have particular depth in oncology, but also have expertise in infectious...

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD...

Asset scouting for a well-capitalized Swiss pharma company Alacrita been engaged by a well-capitalized Swiss pharma company to scout and identify early stage in-licensing opportunities from the New...

Challenge: The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...

Challenge: An emerging specialty pharma company facing an urgent partnering transaction deadline needed to assess the likely reimbursement and pricing of a new therapy in a crowded haematology...

Medical device 510(k) submission strategy Alacrita’s client had successfully CE marked a novel lung function device, and the next step in the commercial strategy was to obtain 510(k) clearance to...

A venture-backed biotech company, developing a clinical stage asset for the treatment of early stage cancer, was populating a dataroom and preparing for negotiations with a major pharmaceutical...

Alacrita acts as a life science Professional Employment Organization to ex-US life science companies looking to access the US market.

Challenge: A US medical device company wanted to understand how UK payers would view their technology. They engaged Alacrita to find out.

Alacrita’s radiopharmaceuticals consultants developed an R&D strategy for a major nuclear physics research institute looking to build a capability in nuclear medicine. The project was led by an...